1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Fusion Antibodies plc

Fusion Antibodies plc

FAB.L
Fusion Antibodies plcGB flagLondon Stock Exchange
12.00
GBp
+0.50
- -
15.02MMarket Cap
Fusion Antibodies plc
FAB.L
(London Stock Exchange)

Recent

price

12.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.04
0.07
0.09
0.17
0.1
0.18
0.16
0.18
0.11
0.02
0.02
Revenue per Share
- -
0.05
0.01
-0.04
-0.06
-0.03
-0.11
-0.05
-0.1
-0.04
-0.02
Basic EPS, GAAP
-0.01
0.01
-0.01
-0.02
-0.11
-0.01
-0.06
-0.02
-0.07
-0.03
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.27
-0.21
-0.2
0.11
0.02
- -
-0.11
-0.15
-0.25
-0.11
-0.08
Book Value per Share
0.01
0.07
0.08
0.41
0.24
0.22
0.19
0.14
0.04
0.03
0.01
Tangible Book Value per Share
22
22
22
16
22
22
25
26
26
56
96
Basic Weighted Avg Shares
1
1
2
3
2
4
4
5
3
1
2
Sales/Revenue/Turnover
-10.86
1.87
6.61
-26.41
-69.11
-27.19
-29.99
-27.61
-98.52
-201.32
-90.53
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
Depreciation Expense
- -
1
- -
-1
-1
-1
-3
-1
-3
-2
-2
Net Income, GAAP
- -
- -
4.73
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-9.36
77.91
6.27
-26.01
-57.93
-17.89
-69.6
-25.01
-89.49
-195.95
-87.18
Profit Margin (%)
- -
- -
- -
5
3
2
4
3
1
2
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
1
2
7
5
5
5
4
1
2
1
Total Equity
- -
- -
7.66
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
-2.63
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-115.71
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
93.82%
-19.26%
-62.69%
Free Cash Flow
85.88%
117.45%
-22.42%
Net Income, GAAP
-185.7%
67.27%
-23.05%
Sales/Revenue/Turnover
18.7%
-1.05%
72.98%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
2
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.04
2025
- -
- -
- -
- -
-0.02
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Zai Lab Limited (ZLAB)
Oncoinvent ASA (ONCIN.OL)
Hutech21 Co., Ltd. (CLGZF)
HEALTHeUNIVERSE, Inc. (HLUN)
Therapeutic Solutions International, Inc. (TSOI)
Karolinska Development AB (publ) (KDEVF)
Business
Fusion Antibodies plc specializes in preclinical antibody discovery, engineering, and supply services for therapeutic drug and diagnostic applications, offering monoclonal antibody discovery and development; antibody sequencing, engineering, and humanization using its proprietary CDRx™ platform; rational affinity maturation; recombinant protein expression; and stable cell line development including cGMP scale-up. Established in 2001 as a spin-out from Queen’s University Belfast and headquartered in Belfast, the company serves a global client base including eight of the top ten global pharmaceutical companies. Recent strategic developments include an expanded collaboration agreement with the US National Cancer Institute to humanize camelid nanobodies for CAR-T therapy applications, and selection by a major European-based global pharmaceutical firm for a multi-target integrated therapeutic antibody services project covering humanization and supply, expected to generate significant revenue. Additionally, Fusion Antibodies secured up to £545,000 in Innovate UK funding to advance a DR5 antibody for treatment-resistant cancers and announced new R&D projects including a bispecific antigen toolkit. The company maintains ongoing revenue growth and broader platform development under CEO Adrian Kinkaid's leadership, aiming to reduce dependence on smaller clients by targeting major pharmaceutical collaborations and leveraging novel technologies in antibody engineering and development. Fusion Antibodies maintains operations primarily in the UK and collaborates internationally across the pharmaceutical and biotech sectors to accelerate drug discovery and therapeutic innovation.